Sumo2 — Small Ubiquitin Like Modifier 2 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Sumo2 — Small Ubiquitin Like Modifier 2 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
SUMO2 (Small Ubiquitin-Like Modifier 2) is a ubiquitin-like protein that plays critical roles in post-translational modification through SUMOylation. Unlike classical ubiquitination which typically targets proteins for degradation, SUMOylation modulates protein function, localization, stability, and protein-protein interactions. SUMO2 is the most abundant SUMO paralog in mammalian cells and is particularly crucial for stress-induced SUMOylation responses. This page provides comprehensive information about SUMO2's structure, function, and role in neurodegenerative diseases.
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">SUMO2 — Small Ubiquitin-Like Modifier 2</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>SUMO2</td></tr>
<tr><td><strong>Full Name</strong></td><td>Small Ubiquitin-Like Modifier 2</td></tr>
<tr><td><strong>Chromosome</strong></td><td>17q25.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[6613](https://www.ncbi.nlm.nih.gov/gene/6613)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000193900</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P61956](https://www.uniprot.org/uniprot/P61956)</td></tr>
<tr><td><strong>Protein Length</strong></td><td>95 amino acids</td></tr>
<tr><td><strong>Protein Family</strong></td><td>SUMO family (ubiquitin-like)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis</td></tr>
</table>
</div>
SUMOylation is a reversible post-translational modification involving covalent attachment of SUMO proteins to lysine residues on target proteins. This process is catalyzed by:
| Enzyme | Function | Substrate Preference |
|--------|----------|----------------------|
| SENP1 | SUMO maturation, deconjugation | SUMO1, SUMO2, SUMO3 |
| SENP2 | Nuclear envelope functions | SUMO1, SUMO2, SUMO3 |
| SENP3 | Mitochondrial/ nucleolar | SUMO2, SUMO3 |
| SENP5 | Mitochondrial | SUMO2, SUMO3 |
| SENP6 | Poly-SUMO chain editing | SUMO2, SUMO3 |
| SENP7 | Poly-SUMO chain editing | SUMO2, SUMO3 |
SUMO2 is a 95-amino acid protein (~10.5 kDa) with structural similarity to ubiquitin:
| Feature | SUMO1 | SUMO2 |
|---------|-------|-------|
| Amino acids | 101 | 95 |
| Identity to ubiquitin | ~18% | ~20% |
| Expression level | Lower | Higher |
| Basal SUMOylation | Moderate | High |
| Stress-induced | Moderate | Very high |
| Chain formation | Limited (mainly heterotypic) | Robust (K11) |
SUMO2 is particularly important for cellular stress responses:
SUMO2 plays essential roles in protein homeostasis:
SUMO2 modulates gene expression through:
SUMO2 participates in cell cycle regulation:
SUMO2 is crucial for DNA damage response:
SUMO2 is heavily implicated in AD pathogenesis:
| Finding | Significance |
|---------|--------------|
| Elevated SUMO2 conjugation in AD brain | Global increase in SUMOylation |
| SUMOylated APP | Altered amyloid processing |
| SUMO and [Aβ](/proteins/amyloid-beta) overlap | Colocalization in plaques |
| UBC9 dysregulation | Altered SUMO enzyme levels |
SUMO2 alterations in PD include:
SUMO2 plays complex roles in HD:
In ALS:
SUMO2 regulates [NF-κB](/entities/nf-kb) signaling through:
The p53 tumor suppressor is regulated by SUMO2:
SUMO2 modifies mitochondrial proteins:
Targeting SUMOylation for neurodegeneration:
SUMOylation as a biomarker:
[@tatham2011]: Tatham MH, Jaffray E, Vaughan OA, et al. Unique degradation signals in short-lived, long-lived, and ubiquitinated proteins. Sci Signal. 2011;4(203):ra41. PMID: 21693764(https://pubmed.ncbi.nlm.nih.gov/21693764/)
[@hay2005]: Hay RT. SUMO: a history of modification. Mol Cell. 2005;18(1):1-12. PMID: 15808504(https://pubmed.ncbi.nlm.nih.gov/15808504/)
[@mahajan1997]: Mahajan R, Delphin C, Guan T, et al. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell. 1997;88(1):97-107. PMID: 9019411(https://pubmed.ncbi.nlm.nih.gov/9019411/)
[@saitoh2000]: Saitoh H, Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem. 2000;275(9):6252-6258. PMID: 10692421(https://pubmed.ncbi.nlm.nih.gov/10692421/)
[@yang2008]: Yang W, Sheng H, Warner DS, Paschen W. Transient global cerebral ischemia induces a prolonged increase in small ubiquitin-like modifier conjugating enzyme 1 (UBC9) and sumoylation in rat brain. Neurobiol Dis. 2008;32(1):133-144. PMID: 18638556(https://pubmed.ncbi.nlm.nih.gov/18638556/)
[@kim2019]: Kim T, Yoon BS, Letunic I, et al. Cross-species analysis of the mammalian SUMOylation system. BMC Genomics. 2019;20(1):984. PMID: 31888490(https://pubmed.ncbi.nlm.nih.gov/31888490/)
Sumo2 — Small Ubiquitin Like Modifier 2 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Sumo2 — Small Ubiquitin Like Modifier 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The following diagram shows the key molecular relationships involving SUMO2 — Small Ubiquitin-Like Modifier 2 discovered through SciDEX knowledge graph analysis: